Q4 2019 13F Holders as of 31 Dec 2019
-
Type / Class
-
Equity / Ordinary Shares, par value GBP 0.001 per share
-
Shares outstanding
-
1,571,428,571
-
Total 13F shares
-
64,873,900
-
Share change
-
-3,230,610
-
Total reported value
-
$77,850,537
-
Price per share
-
$1.20
-
Number of holders
-
36
-
Value change
-
-$4,188,215
-
Number of buys
-
15
-
Number of sells
-
20
Institutional Holders of Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) as of Q4 2019
As of 31 Dec 2019 Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) had 36 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 64,873,900 shares of stock of the company.
Largest 10 holders included Matrix Capital Management Company, LP, NEA Management Company, LLC, Capital World Investors, BAILLIE GIFFORD & CO, FMR LLC, RENAISSANCE TECHNOLOGIES LLC, ORBIMED ADVISORS LLC, Man Group plc, Polygon Management Ltd., and Rock Springs Capital Management LP.
This table shows 36 institutional shareholders of the security as of 31 Dec 2019.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.